DDInter927 DDInter1616
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with
Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.
Romidepsin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Romidepsin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nifedipine
Romidepsin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Histrelin
Romidepsin {u} may lead to a major life threatening interaction when taken with {v} Bacillus calmette-guerin substrain tice live antigen
Romidepsin {u} may lead to a major life threatening interaction when taken with {v} Halofantrine
Romidepsin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Romidepsin may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Romidepsin may lead to a major life threatening interaction when taken with Halofantrine